Crenezumab

Drug Profile

Crenezumab

Alternative Names: Anti-amyloid-beta monoclonal antibody; Anti-Aβ mAb; MABT5102A; R 5490245; RG 7412; RO 5490245

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AC Immune; Universidad de Antioquia
  • Developer AC Immune; Chugai Pharmaceutical; Genentech; Universidad de Antioquia
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 21 Mar 2017 Roche initiates the phase III CREAD 2 trial in Alzheimer's disease in Spain (BN29553; EudraCT2016-003288-20).
  • 28 Feb 2017 Genentech plans a phase III CREAD2 trial for Alzheimer's disease
  • 01 Feb 2017 Genentech completes a phase II long-term safety extension trial for Alzheimer's disease in USA, Canada, France, Germany, Spain and United Kingdom (IV) (NCT01723826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top